511 results match your criteria rituximab 1000


An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development.

Expert Opin Pharmacother 2021 Jul 29:1-13. Epub 2021 Jul 29.

Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Barcelona, Spain.

: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that may affect 3 in 1,000 people within the general population. The therapeutic scenario is complex, and no therapy has proved to be able to modify the natural course of the disease, nor to prevent the most severe systemic complications.: Recently, the EULAR 2020 Recommendations for pSS have underlined the low level of evidence supporting efficacious therapeutic approaches, lacking a definition of specific treatment targets and being far from the 'disease modification' concept that is frequently used in other diseases. Read More

View Article and Full-Text PDF

Rituximab for the Treatment of Refractory Cardiac Sarcoidosis-A Single Center Experience.

J Card Fail 2021 Jul 25. Epub 2021 Jul 25.

Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Division of Epidemiology, Department of Health Sciences Research, Rochester, MN, USA.

Objective: To examine the effect of anti-B cell therapy (rituximab) on cardiac inflammation and function in corticosteroid-refractory cardiac sarcoidosis.

Background: Cardiac sarcoidosis (CS) is a rare cause of cardiomyopathy characterized by granulomatous inflammation involving the myocardium. While typically responsive to corticosteroid treatment, there is a critical need for identifying effective steroid-sparing agents for disease control. Read More

View Article and Full-Text PDF

Chronic Onset Form of Anti-HMG-CoA Reductase Myopathy.

Eur J Case Rep Intern Med 2021 8;8(7):002672. Epub 2021 Jun 8.

Service de Rhumatologie, Hôpitaux Universitaires de Strasbourg, France.

We report a case of anti-HMGCR myopathy mimicking limb-girdle muscular dystrophy in a 27-year-old male patient with no history of statin intake and presenting with a chronic onset form over 3 years. Treatment with prednisone and methotrexate was initiated with an insufficient response, so intravenous immunoglobulin was added. One year after initial treatment was started, as levels of creatine kinase (CK) were >1000 U/l, treatment with rituximab was added. Read More

View Article and Full-Text PDF

Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.

Neurology 2021 Jun 30. Epub 2021 Jun 30.

CORe, Department of Medicine, University of Melbourne, Melbourne, Australia

Objective: To compare the clinical effectiveness of high- and low-efficacy treatments in patients with recently active and inactive secondary progressive multiple sclerosis (SPMS) after accounting for therapeutic lag.

Methods: Patients treated with high- (natalizumab, alemtuzumab, mitoxantrone, ocrelizumab, rituximab, cladribine, fingolimod) or low-efficacy (interferon β, glatiramer acetate, teriflunomide) therapies after SPMS onset were selected from MSBase and OFSEP, two large observational cohorts. Therapeutic lag was estimated for each patient based on their demographic and clinical characteristics. Read More

View Article and Full-Text PDF

What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?

Turk J Gastroenterol 2021 03;32(3):294-301

Department of Gynecologic Oncology, Gynecology and Obstetrics, Çukurova University School of Medicine, Adana, Turkey.

Background: Reactivation of Hepatitis B (HBVr) related to immunosuppressive drug therapy (ISDT) in patients with resolved and past infection is a challenging entity. The number of prospective long-term studies is limited.

Methods: Two groups of patients with resolved and past HBV infection were analyzed prospectively. Read More

View Article and Full-Text PDF

Risk of Herpes Zoster Among Psoriasis Patients Taking Biologics: A Network Meta-Analysis of Cohort Studies.

Front Med (Lausanne) 2021 4;8:665559. Epub 2021 Jun 4.

Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.

Herpes zoster (HZ) has raised public concern. An increasing incidence of HZ can be seen in the immunocompromised population, such as the psoriasis patients taking biologics. Real-world evidences are still needed to investigate the risks of HZ among patients receiving different biologics treatments. Read More

View Article and Full-Text PDF

Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis.

ACR Open Rheumatol 2021 Jul 11;3(7):484-494. Epub 2021 Jun 11.

Canadian Network for Research on Vasculitides, Hôpital Sacré-Coeur de Montréal, and University of Montreal, Montreal, Quebec, Canada.

Objective: The objective of this study was to compare the efficacy and safety of two rituximab (RTX) regimens for the induction of remission in severe antineutrophil cytoplasm antibody-associated vasculitis (AAV): the four-dose (375 mg/m intravenously weekly) versus the two-dose (1000 mg intravenously biweekly) regimen.

Methods: A systematic review was performed to identify studies using the four- and/or two-dose RTX regimens for induction of remission in severe AAV. Disease status 6 months after RTX infusion was required for inclusion. Read More

View Article and Full-Text PDF

Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

N Engl J Med 2021 06 19;384(24):2295-2305. Epub 2021 May 19.

From the Perelman School of Medicine, University of Pennsylvania, and the Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia (V.P.W.); the Department of Dermatology, Rouen University Hospital and INSERM 1234, Normandie Université, Rouen (P.J.), and the Department of Dermatology, Groupe Hospitalier Paris Seine-Saint-Denis, Assistance Publique-Hôpitaux de Paris and INSERM Unité Mixte de Recherche 1125, Bobigny (F.C.) - all in France; the Sackler School of Medicine, Tel Aviv University, Tel Aviv, and Rabin Medical Center, Petah Tikva - both in Israel (D.M.); the Department of Dermatology, University of California, Davis, School of Medicine, Sacramento (E.M.), and Genentech, South San Francisco (A.K., D.M.C.) - both in California; Roche Products, Welwyn Garden City, United Kingdom (P.L.); F. Hoffmann-La Roche, Basel, Switzerland (L.G.); and Roche Products, Mississauga, ON, Canada (P.P.).

Background: Rituximab and mycophenolate mofetil are used to treat pemphigus vulgaris, but they have not been adequately compared in clinical trials.

Methods: In a randomized, controlled trial, we assigned patients with moderate-to-severe pemphigus vulgaris in a 1:1 ratio to receive intravenous rituximab (1000 mg on days 1, 15, 168, and 182) or oral mycophenolate mofetil (2 g per day), in addition to an oral glucocorticoid administered on the same tapering schedule in the two groups. The primary end point was sustained complete remission at week 52, defined as the healing of lesions with no new active lesions, as reflected by a Pemphigus Disease Area Index (PDAI) activity score of 0 (on a scale of 0 to 250, with higher scores indicating greater disease severity), for at least 16 weeks without the use of glucocorticoids. Read More

View Article and Full-Text PDF

Biotherapies in Medical Practice: A Review and the Nigerian Experience.

West Afr J Med 2021 May;38(5):486-493

Internal Medicine Unit, Kubwa General Hospital, Abuja, Nigeria.

Biologics or Biological agents are pharmaceuticals manufactured, extracted from or semi synthesized from biological sources and used in the diagnosis, treatment or prevention of diseases. When used for rheumatic diseases, they are monoclonal antibodies targeting wide range of peptide mediators (cytokines), receptors and cells. They have complex structures and are about 200 to 1000 times larger than chemical molecule drugs. Read More

View Article and Full-Text PDF

Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus.

J Dermatolog Treat 2021 Jun 8:1-8. Epub 2021 Jun 8.

Dermatology and Venereology, Akdeniz University School of Medicine, Antalya, Turkey.

Background: Rituximab appears to be effective for treating pemphigus, although there are limited long-term data.

Methods: This retrospective single-center study evaluated patients with conventional treatment-resistant pemphigus who received rituximab during September 2010-December 2019. The first rituximab cycle was based on the rheumatoid arthritis protocol in all patients except one patient, and additional single doses (500 mg or 1000 mg) were administered after clinical and/or serological relapse. Read More

View Article and Full-Text PDF

Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.

Lancet Glob Health 2021 Jul 19;9(7):e1008-e1016. Epub 2021 May 19.

Center for Global Health, National Cancer Institute, Rockville, MD, USA. Electronic address:

Background: There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with DLBCL in Malawi.

Methods: This prospective, single-arm, non-randomised phase 1/2 clinical trial was done at Kamuzu Central Hospital Cancer Clinic (Lilongwe, Malawi). Read More

View Article and Full-Text PDF

Efficacy of Rituximab on Rheumatoid Leptomeningitis as the First Symptom of Rheumatoid Arthritis.

Eur J Case Rep Intern Med 2021 21;8(4):002358. Epub 2021 Apr 21.

Service de Rhumatologie, CHRU Besançon, Besançon, France.

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized mainly by arthritis, with the possible occurrence of extra-articular manifestations. We report the case of a patient who developed leptomeningitis as the first sign of RA, one year before the diagnosis of RA. Methylprednisolone 1000 mg was given intravenously. Read More

View Article and Full-Text PDF

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).

BMC Cancer 2021 Apr 6;21(1):358. Epub 2021 Apr 6.

Division of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.

Background: A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma receiving the first R-CHOP cycle.

Methods: This was a subanalysis of the retrospective observational study STOP FN in NHL 2 (UMIN000029534). Patient characteristics, changes in neutrophil count, incidence and severity of neutropenia, and risk factors for dose reduction/delay of R-CHOP were assessed by G-CSF formulation. Read More

View Article and Full-Text PDF

Disease-modifying treatments for primary autoimmune haemolytic anaemia.

Cochrane Database Syst Rev 2021 03 26;3:CD012493. Epub 2021 Mar 26.

Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

Background: Primary autoimmune haemolytic anaemia (AIHA) is an autoantibody mediated condition characterised by a variable disease course. A myriad of immunomodulatory agents have been employed but there is a paucity of evidence to support their use or compare their effectiveness.

Objectives: To determine the effects of various disease-modifying treatment modalities in people with AHIHA. Read More

View Article and Full-Text PDF

Rituximab in Patients with Acute ST-elevation Myocardial Infarction (RITA-MI): an Experimental Medicine Safety Study.

Cardiovasc Res 2021 Mar 30. Epub 2021 Mar 30.

Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.

Aims: In pre-clinical models of acute myocardial infarction (MI), mature B cells mobilise inflammatory monocytes into the heart, leading to increased infarct size and deterioration of cardiac function, whilst anti-CD20 antibody mediated depletion of B cells limits myocardial injury and improves cardiac function. Rituximab is a monoclonal anti-CD20 antibody targeted against human B cells. However, its use in cardiovascular disease is untested and is currently contraindicated. Read More

View Article and Full-Text PDF

Multiple sclerosis, rituximab, and COVID-19.

Ann Clin Transl Neurol 2021 04 30;8(4):938-943. Epub 2021 Mar 30.

Department of Research & Evaluation, Southern California Permanente Medical Group, Pasadena, CA, USA.

We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab-treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID-19, compared to the 4. Read More

View Article and Full-Text PDF

Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial.

Taiwan J Ophthalmol 2021 Jan-Mar;11(1):64-70. Epub 2020 Jul 27.

Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.

Purpose: This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR).

Materials And Methods: Five npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All patients received a cycle of 1000 mg intravenous rituximab at weeks 0 and 2, with a second cycle of rituximab 6 to 9 months later. Read More

View Article and Full-Text PDF

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).

Rheumatology (Oxford) 2021 Mar 19. Epub 2021 Mar 19.

Division of Rheumatology, University Hospital Frankfurt, Goethe University.

Objective: To investigate the efficacy and safety of rituximab + LEF in patients with RA.

Methods: In this investigator-initiated, randomized, double-blind, placebo-controlled phase 3 trial, patients with an inadequate response to LEF who had failed one or more DMARD were randomly assigned 2:1 to i.v. Read More

View Article and Full-Text PDF

Opsoclonus myoclonus syndrome in a postpartum period.

Mult Scler Relat Disord 2021 May 24;50:102862. Epub 2021 Feb 24.

University of Kansas Medical Center, Department of Neurology, Kansas City, KS, USA.

Background: Opsoclonus-myoclonus syndrome (OMS) is a rare neuroimmunologic disorder characterized by opsoclonus, myoclonic jerks mostly in the face and limbs, cerebellar ataxia, tremors, and encephalopathy. OMS is rare in adults and exceedingly rarer in pregnancy, as only a few cases in pregnancy have been reported. We present what we understand is the first case of postpartum OMS. Read More

View Article and Full-Text PDF

Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.

Blood 2021 Jun;137(25):3507-3517

Department of Molecular Biotechnology and Health Sciences, University of Torino-Division of Hematology, Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino, Turin, Italy.

Autoimmune cytopenias (AICs) affect 5% to 9% of patients with chronic lymphocytic leukemia (CLL). Targeted drugs-ibrutinib, idelalisib, and venetoclax-have a prominent role in the treatment of CLL, but their impact on CLL-associated AICs is largely unknown. In this study, we evaluated the characteristics and outcome of preexisting AICs and described the incidence, quality, and management of treatment-emergent AICs during therapy with targeted drugs in patients with CLL. Read More

View Article and Full-Text PDF

Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.

Am J Respir Crit Care Med 2021 Jul;204(2):209-221

Division of Pulmonary, Allergy, and Critical Care Medicine and.

Systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. We investigated the safety and efficacy of B-cell depletion for SSc-PAH. Read More

View Article and Full-Text PDF

Treatment of Pemphigus with Rituximab: Real-Life Experience in a Cohort of 117 Patients in Israel.

Dermatology 2021 10;237(3):450-456. Epub 2021 Feb 10.

Division of Dermatology, Rabin Medical Center, Petah Tiqva, Israel.

Background: A combined regimen of rituximab with corticosteroids for the treatment of pemphigus was effective in a prospective randomized controlled trial.

Objective: To assess real-life response to rituximab in patients with pemphigus.

Methods: A retrospective cohort of patients with pemphigus treated with ≥1 rituximab cycles (1,000 mg on days 0 and 14). Read More

View Article and Full-Text PDF
February 2021

Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients.

Saudi J Kidney Dis Transpl 2020 Nov-Dec;31(6):1432-1438

Renal Transplant Unit, National Institute of Solid Organ and Tissue Transplantation, Dow University Hospital, Karachi, Pakistan.

Kidney transplantation has indisputably revamped renal medicine and restored hope among patients coming across fatal end-stage renal disease. However, sensitization of human leukocyte antigen (HLA) triggers extensive immunological fences to successful kidney transplantation and henceforth, transplant candidates are frequently demoted to the ever-growing waiting list owing to preformed donor specific antibodies (DSAs). Over the past few years, the advent of desensitization protocols has significantly overpowered the immunological barriers and enhanced the outcomes of kidney transplant recipients with DSAs against HLA. Read More

View Article and Full-Text PDF
February 2021

Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC-MS.

Bioanalysis 2021 Feb 5;13(4):265-276. Epub 2021 Feb 5.

Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan.

We aimed to develop an easy, low-cost and versatile mass spectrometric method for the bioanalysis of a therapeutic monoclonal antibody (mAb) in human serum that employs peptide adsorption-controlled (PAC)-LC/MS using selected reaction monitoring mode (LC-MS/MS-SRM). Rituximab was used as a model mAb. To apply the method to human serum samples, a peptide of the complementarity-determining region was selected as the surrogate peptide. Read More

View Article and Full-Text PDF
February 2021

Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients.

Transplantation 2021 08;105(8):1818-1824

Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.

Background: Tocilizumab is an interleukin-6 receptor antagonist recently described as a promising treatment for antibody-mediated rejection. We compared infectious complications among tocilizumab-treated kidney transplant patients with those receiving intravenous immunoglobulin (IVIG)/rituximab.

Methods: Infections occurring among 148 kidney recipients treated with tocilizumab 8 mg/kg IV monthly (n = 83) or IVIG/rituximab (n = 65) for donor-specific antibodies and antibody-mediated rejection through 1 year after treatment cessation were reviewed. Read More

View Article and Full-Text PDF

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis.

Neurology 2021 03 29;96(11):e1574-e1584. Epub 2021 Jan 29.

From the Department of Clinical Neuroscience (P.A., F.P.) and Clinical Epidemiology Division (P.A., T.F.), Department of Medicine Solna, Karolinska Institutet, Stockholm; Department of Neuroscience (J.B.), Uppsala University; Department of Clinical Neuroscience (J.L.), Institute of Neuroscience and Physiology, University of Gothenburg; and Academic Specialist Centre (F.P.), Stockholm Health Services, Sweden.

Objective: To assess safety outcomes for the induction therapies alemtuzumab and autologous hematopoietic stem cell transplantation (AHSCT) compared to noninduction disease-modifying therapies.

Methods: We performed a population-based cohort study linking the Swedish Multiple Sclerosis Register to national health care registers. Alemtuzumab, AHSCT, and a matched reference group of noninduction therapies (natalizumab, dimethyl fumarate, rituximab, fingolimod) were included if started between 2008 and 2017. Read More

View Article and Full-Text PDF

MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.

Lancet Haematol 2021 Feb;8(2):e110-e121

Università Degli Studi di Perugia-AO Santa Maria, Terni, Italy.

Background: Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopoietic stem-cell transplantation (HSCT) in patients with secondary CNS lymphoma.

Methods: This international, single-arm, phase 2 trial was done in 24 hospitals in Italy, the UK, the Netherlands, and Switzerland. Read More

View Article and Full-Text PDF
February 2021

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis.

RMD Open 2021 01;7(1)

Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin Bicêtre Hospital, Le Kremlin-Bicêtre, France.

Objective: Peripheral ulcerative keratitis (PUK) is a rare but severe ocular complication of rheumatoid arthritis (RA). It can be considered as an ocular manifestation of rheumatoid vasculitis (RV). Our case series aimed to evaluate the efficacy of rituximab (RTX) for PUK occurring in patients with RA. Read More

View Article and Full-Text PDF
January 2021

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.

Lancet 2021 01;397(10271):305-317

Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, UK; Department of Rheumatology, Mile End Hospital, Barts Health NHS Trust, London, UK. Electronic address:

Background: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cells-the target for rituximab-in the main disease tissue (joint synovium), we hypothesised that, in these patients, the IL-6 receptor inhibitor tocilizumab would be more effective. The aim of this trial was to compare the effect of tocilizumab with rituximab in patients with rheumatoid arthritis who had an inadequate response to anti-tumour necrosis factor (TNF) stratified for synovial B-cell status. Read More

View Article and Full-Text PDF
January 2021

Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis.

J Neurol 2021 Jun 21;268(6):2161-2168. Epub 2021 Jan 21.

Department of Clinical Sciences, Neurosciences, Umeå University, Umea, Sweden.

Background: Rituximab is safe and effective for treating relapsing-remitting multiple sclerosis (RRMS) according to phase II and observational studies. There are limited data on disease activity after discontinuation and dose reduction. The objective of this study was to evaluate the effects on inflammatory disease activity after discontinuation or dose reduction of rituximab in patients with RRMS or clinically isolated syndrome (CIS). Read More

View Article and Full-Text PDF